Siklos (hydroxycarbamide)
- Region
- 🇪🇺 EU
- Active substance
- hydroxycarbamide
- Company
- Theravia
- Status
- Authorised
- Therapeutic area
- Anemia, Sickle Cell
- EU approval
- Fri 29 Jun 2007
- Application
- EMEA/H/C/000689
- ATC
- L01XX05
- Official record
- www.ema.europa.eu
Indication
Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic sickle-cell syndrome.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Xromi Authorised · Lipomed GmbH
Follow Siklos
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.